SEARCH

SEARCH BY CITATION

References

  • 1
    Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al.Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466476.
  • 2
    Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy 2009;64:8595.
  • 3
    Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011;106:S12S16.
  • 4
    Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004;46:398412.
  • 5
    Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold–high cost to society. Allergy 2010;65:776783.
  • 6
    Incorvaia C, Masieri S, Berto P, Scurati S, Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. Allergy Asthma Clin Immunol 2010;6:29.
  • 7
    Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011;41:11771200.
  • 8
    Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R et al. Use of pharmacoeconomics information–report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003;6:407416.
  • 9
    Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, edn 3. Oxford: Oxford University Press, 2005.
  • 10
    Ariano R, Berto P, Tracci D, Incorvaia C, Frati F. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006;27:159163.
  • 11
    Ariano R, Berto P, Incorvaia C, Di CG, Boccardo R, La GS et al. Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. Ann Allergy Asthma Immunol 2009;103:254259.
  • 12
    Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective. Clin Exp Allergy 2007;37:772779.
  • 13
    Berto P, Bassi M, Incorvaia C, Frati F, Puccinelli P, Giaquinto C et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol 2005;37:303308.
  • 14
    Berto P, Passalacqua G, Crimi N, Frati F, Ortolani C, Senna G et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006;97:615621.
  • 15
    Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316324.
  • 16
    Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med 2007;101:18851894.
  • 17
    Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501506.
  • 18
    Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007;23:11131120.
  • 19
    Mauro M, Russello M, Alesina R, Sillano V, Alessandrini A, Dama A et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol 2006;38:3134.
  • 20
    Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008;63:16241629.
  • 21
    Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol 2007;39:148156.
  • 22
    Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005;33:296302.
  • 23
    Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2008;100:482489.
  • 24
    Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17:3752.
  • 25
    Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008;8:585589.
  • 26
    Ciprandi G, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M et al. Economic evaluation of sublingual immunotherapy: an analysis of literature. Eur Ann Allergy Clin Immunol 2007;39:2126.
  • 27
    Hagen A, Gorenoi V, Schonermark MP. Specific immunotherapy (SIT) in the treatment of allergic rhinitis. GMS Health Technol Assess 2010;6:Doc01.
  • 28
    Incorvaia C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 2007;39:1720.
  • 29
    Incorvaia C, Ariano R, Berto P, Ciprandi G, Leo G, Boccardo R et al. Economic aspects of sublingual immunotherapy. Int J Immunopathol Pharmacol 2009;22:2730.
  • 30
    Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22:345361.
  • 31
    Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. Ugeskr Laeger 2008;170:138142.
  • 32
    Valovirta E, Berstad AK, de BJ, Bufe A, Eng P, Halken S et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther 2011;33:15371546.
  • 33
    Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717725.
  • 34
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:412.
  • 35
    Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004;20:19371952.
  • 36
    Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L et al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol 2001;54:610618.
  • 37
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:7783.
  • 38
    The EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199208.
  • 39
    Raftery J. Review of NICE's recommendations, 1999–2005. BMJ 2006;332:12661268.